Literature DB >> 31389188

Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.

S E Bosma1, A J Rueten-Budde2, C Lancia2, A Ranft3,4, U Dirksen3,4, A D Krol5, H Gelderblom6, M A J van de Sande1, P D S Dijkstra1, M Fiocco2,7.   

Abstract

BACKGROUND: We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. PROCEDURE: Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM ± LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models.
RESULTS: The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75).
CONCLUSION: Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
© 2019 The Authors. Pediatric Blood & Cancer Published byWiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; multistate model; personalized medicine; prediction; survival

Mesh:

Year:  2019        PMID: 31389188     DOI: 10.1002/pbc.27943

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone.

Authors:  Lei Zhang; Lu Xiong; Li-Mei Wu; Wen-Hui Shen; Ping Zhou; Chen-Lu Lian; Wen-Tong Zhang; San-Gang Wu
Journal:  J Bone Oncol       Date:  2021-08-02       Impact factor: 4.072

2.  Bone sarcoma: success through interdisciplinary collaboration.

Authors:  Stefanie Hecker-Nolting; Ana Maia Ferreira; Stefan S Bielack
Journal:  J Child Orthop       Date:  2021-08-20       Impact factor: 1.548

3.  What Are the Results of Limb Salvage Surgery for Primary Malignant Bone Tumor in the Forearm?

Authors:  Weifeng Liu; Yongkun Yang; Tao Jin; Yang Sun; Yuan Li; Lin Hao; Qing Zhang; Xiaohui Niu
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

4.  Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial.

Authors:  Audinga-Dea Hazewinkel; Carlo Lancia; Jakob Anninga; Michiel van de Sande; Jeremy Whelan; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2022-03-04       Impact factor: 2.692

5.  Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry.

Authors:  Chuchu Liu; Anja J Rueten-Budde; Andreas Ranft; Uta Dirksen; Hans Gelderblom; Marta Fiocco
Journal:  BMJ Open       Date:  2020-10-12       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.